{"id":59274,"date":"2024-09-10T12:05:05","date_gmt":"2024-09-10T12:05:05","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/09\/10\/dermatologic-surgery-journal-publishes-special-issue-on-neuromodulators\/"},"modified":"2024-09-10T12:05:05","modified_gmt":"2024-09-10T12:05:05","slug":"dermatologic-surgery-journal-publishes-special-issue-on-neuromodulators","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/dermatologic-surgery-journal-publishes-special-issue-on-neuromodulators\/","title":{"rendered":"“Dermatologic Surgery” Journal Publishes Special Issue on Neuromodulators"},"content":{"rendered":"
\n

Guest Editors Drs. Jean Carruthers and Seth L. Matarasso have assembled a special issue of peer-reviewed articles sharing the current state of the art and the future potential use of neurotoxins. The issue spans a diverse patient population and indications to offer viewpoints from leading experts on the basic science of botulinum toxin, anatomical considerations and potential adverse events.<\/em><\/p>\n

Schaumburg, IL, Sept. 10, 2024 (GLOBE NEWSWIRE) — Dermatologic Surgery<\/i>, the official scientific journal of the American Society for Dermatologic Surgery (ASDS), has published a special issue<\/u><\/strong><\/a> dedicated to research and innovations in the use of neuromodulators (such as BOTOX\u00ae, Dysport\u00ae, Xeomin\u00ae and Jeuveau\u00ae).<\/p>\n

\u201cFor this special issue, we identified practice areas that, although non-FDA\u2013approved, were novel and would be educational to those physicians looking to expand their scope of practice,\u201d said Drs. Carruthers and Matarasso. \u201cWe endeavored to find subjects that were diverse and meet the needs of a growing patient population. We included manuscripts on the basic science of botulinum toxin, anatomical considerations and potential adverse events. Certainly, any robust publication should have material that will challenge and pique the reader’s curiosity, so we included topics such as combination therapy, toxins on the horizon, accessory proteins and the potential of reversing the effects of neuromodulators.\u201d <\/p>\n

\u201cThis Special Issue is intended to be a standalone mini textbook on the current state of the art of neuromodulators, bringing together many of the world’s experts on botulinum toxins,\u201d said Editor in Chief William P. Coleman, III, MD. \u201cWe have asked the various manufacturers of these products to support the Special Issue both financially and by contributing their best up-to-date science. As most of the companies that market toxins are represented here, we can expose the reader to many different viewpoints and controversies.\u00a0<\/p>\n

Articles in the Special Issue include:<\/p>\n